Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...

Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

The CONNECT study is of similar magnitude to previous randomized controlled trials, such as JDRF, DIAMOND and MOBILE, which demonstrated the benefits of CGM use among insulin using people with ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system ...

The upcoming system, for people with Type 1 or Type 2 diabetes ages 18 and up, boosts wear time by 50% over the currently available G7 sensor. (Dexcom) Dexcom has won a clearance from the FDA for its ...